
Please try another search
For the three months ended 31 March 2022, Bellicum Pharmaceuticals Inc revenues was not reported. Net loss decreased 33% to $7.6M. Lower net loss reflects Research & Development Expense decrease of 32% to $4.2M (expense), Change in Fair Value of Warranty Liabili decrease of 30% to $1.6M (expense), Loss on lease termination decrease from $464K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.12 to -$0.25.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0.5 | 5 | 0.7 |
Gross Profit | ||||
Operating Income | -5.94 | -5.1 | -3.04 | -7.79 |
Net Income | -7.56 | 2.53 | 1.23 | -2.2 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 43.43 | 49.14 | 22.37 | 23.96 |
Total Liabilities | 7.97 | 6.71 | 16.5 | 20.16 |
Total Equity | 35.47 | 42.43 | 5.87 | 3.79 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -6.38 | -23.11 | -17.08 | -16.08 |
Cash From Investing Activities | -0.01 | 0.89 | 0.89 | 0.9 |
Cash From Financing Activities | 0 | 32.87 | -0.04 | -0.04 |
Net Change in Cash | -6.39 | 10.66 | -16.23 | -15.22 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review